RxDoctor Payments Data

Amanda Salter, MD

Ophthalmology · Bingham Farms, MINPI 1255644902

Payments from drug & device makers

$3,553in general payments, 2019–2025

Across 135 payments — averaging $26.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$723
  • Tarsus Pharmaceuticals, Inc.$560
  • Sun Pharmaceutical Industries Inc.$399
  • Bausch & Lomb Americas Inc.$364
  • Sight Sciences, Inc.$288
  • Galderma Laboratories, L.p.$208
  • plus $1K from 16 others

What the payments were for

  • Speaking & faculty fees$1504%
  • Food & beverage$3,38595%
  • Education$181%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,553 in reported general payments places this provider in the 75th percentile of 674 ophthalmology providers in Michigan.

See all ophthalmology providers in Michigan

Medicare billing

Part B allowed, 2024
$156,569
Medicare patients
384
Services billed
1,446

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiidraLifitegrast26$42,147
CequaCyclosporine35$35,074
RestasisCyclosporine17$22,425
RocklatanNetarsudil Mesylat/Latanoprost18$12,460
TyrvayaVarenicline Tartrate16$9,516
LumiganBimatoprost19$9,477
Brimonidine Tartrate25$7,675
Cyclosporine16$7,024
Prednisolone Acetate66$1,910
Latanoprost71$1,220
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha75$956
Timolol Maleate52$740
Epinastine Hcl11$615
ErythromycinErythromycin Base28$302
Dorzolamide Hcl15$295

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Xiidra$364$42,14726 claims
Sun Pharmaceutical Industries Inc.Cequa$399$35,07435 claims
AbbVieRestasis, Lumigan$68$31,90236 claims
Aerie Pharmaceuticals, Inc.Rocklatan$24$12,46018 claims
Oyster Point Pharma, Inc.Tyrvaya$133$9,51616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 674 ophthalmology providers in Michigan.

Other ophthalmology in Bingham Farms

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →